Cite
HARVARD Citation
Amiot, A. et al. (2019). Three‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi‐centre cohort study. Alimentary pharmacology & therapeutics. 50 (1), pp. 40-53. [Online].